Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Lymph node number, surface area and lymph node ratio are important prognostic indicators in neoadjuvant chemoradiotherapy treated rectal cancer.

Pitto F, Zoppoli G, Scabini S, Romairone E, Fiocca R, Ballestrero A, Sparavigna M, Malaspina L, Valle L, Grillo F, Mastracci L.

J Clin Pathol. 2019 Sep 25. pii: jclinpath-2019-206139. doi: 10.1136/jclinpath-2019-206139. [Epub ahead of print]

PMID:
31554678
2.

Correction to: Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.

Isnaldi E, Ferraioli D, Ferrando L, Brohée S, Ferrando F, Fregatti P, Bedognetti D, Ballestrero A, Zoppoli G.

Breast Cancer Res Treat. 2019 Oct;177(3):773. doi: 10.1007/s10549-019-05348-z.

PMID:
31300923
3.

Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.

Isnaldi E, Ferraioli D, Ferrando L, Brohée S, Ferrando F, Fregatti P, Bedognetti D, Ballestrero A, Zoppoli G.

Breast Cancer Res Treat. 2019 Sep;177(2):335-343. doi: 10.1007/s10549-019-05313-w. Epub 2019 Jun 20. Erratum in: Breast Cancer Res Treat. 2019 Jul 12;:.

PMID:
31222709
4.

Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely.

Spallarossa P, Tini G, Sarocchi M, Arboscello E, Grossi F, Queirolo P, Zoppoli G, Ameri P.

J Clin Oncol. 2019 Sep 1;37(25):2201-2205. doi: 10.1200/JCO.18.02464. Epub 2019 May 14. No abstract available.

PMID:
31084547
5.

Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer.

Isnaldi E, Garuti A, Cirmena G, Scabini S, Rimini E, Ferrando L, Lia M, Murialdo R, Tixi L, Carminati E, Panaro A, Gallo M, Grillo F, Mastracci L, Repetto L, Fiocca R, Romairone E, Zoppoli G, Ballestrero A.

J Transl Med. 2019 Apr 29;17(1):137. doi: 10.1186/s12967-019-1879-2.

6.

Squalene epoxidase as a promising metabolic target in cancer treatment.

Cirmena G, Franceschelli P, Isnaldi E, Ferrando L, De Mariano M, Ballestrero A, Zoppoli G.

Cancer Lett. 2018 Jul 1;425:13-20. doi: 10.1016/j.canlet.2018.03.034. Epub 2018 Mar 27. Review.

PMID:
29596888
7.

Immune Infiltration in Invasive Lobular Breast Cancer.

Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Rothé F, Buisseret L, Garaud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Bertucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C.

J Natl Cancer Inst. 2018 Jul 1;110(7):768-776. doi: 10.1093/jnci/djx268.

8.

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer.

Ballestrero A, Bedognetti D, Ferraioli D, Franceschelli P, Labidi-Galy SI, Leo E, Murai J, Pommier Y, Tsantoulis P, Vellone VG, Zoppoli G.

J Transl Med. 2017 Oct 2;15(1):199. doi: 10.1186/s12967-017-1296-3.

9.

DNA aneuploidy relationship with patient age and tobacco smoke in OPMDs/OSCCs.

Castagnola P, Gandolfo S, Malacarne D, Aiello C, Marino R, Zoppoli G, Ballestrero A, Giaretti W, Pentenero M.

PLoS One. 2017 Sep 6;12(9):e0184425. doi: 10.1371/journal.pone.0184425. eCollection 2017.

10.

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés AM, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C.

Nat Commun. 2017 Jun 6;8:15759. doi: 10.1038/ncomms15759.

11.

Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.

Zoppoli G, Garuti A, Cirmena G, di Cantogno LV, Botta C, Gallo M, Ferraioli D, Carminati E, Baccini P, Curto M, Fregatti P, Isnaldi E, Lia M, Murialdo R, Friedman D, Sapino A, Ballestrero A.

J Transl Med. 2017 May 1;15(1):91. doi: 10.1186/s12967-017-1195-7.

12.

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés AM, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C.

Nat Commun. 2017 Apr 20;8:14944. doi: 10.1038/ncomms14944. Erratum in: Nat Commun. 2017 Jun 06;8:15759.

13.

Transcriptomic and genomic features of invasive lobular breast cancer.

Desmedt C, Zoppoli G, Sotiriou C, Salgado R.

Semin Cancer Biol. 2017 Jun;44:98-105. doi: 10.1016/j.semcancer.2017.03.007. Epub 2017 Apr 8. Review.

PMID:
28400203
14.

Systems medicine in colorectal cancer: from a mathematical model toward a new type of clinical trial.

Castagnino N, Maffei M, Tortolina L, Zoppoli G, Piras D, Nencioni A, Moran E, Ballestrero A, Patrone F, Parodi S.

Wiley Interdiscip Rev Syst Biol Med. 2016 Jul;8(4):314-36. doi: 10.1002/wsbm.1342. Epub 2016 May 30. Review.

15.

Genomic Characterization of Primary Invasive Lobular Breast Cancer.

Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C.

J Clin Oncol. 2016 Jun 1;34(16):1872-81. doi: 10.1200/JCO.2015.64.0334. Epub 2016 Feb 29.

PMID:
26926684
16.

Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer.

Brown DN, Caffa I, Cirmena G, Piras D, Garuti A, Gallo M, Alberti S, Nencioni A, Ballestrero A, Zoppoli G.

Sci Rep. 2016 Jan 18;6:19435. doi: 10.1038/srep19435.

17.

Systems Medicine in Oncology: Signaling Network Modeling and New-Generation Decision-Support Systems.

Parodi S, Riccardi G, Castagnino N, Tortolina L, Maffei M, Zoppoli G, Nencioni A, Ballestrero A, Patrone F.

Methods Mol Biol. 2016;1386:181-219. doi: 10.1007/978-1-4939-3283-2_10. Review.

PMID:
26677185
18.

Genomic DNA Copy Number Aberrations, Histological Diagnosis, Oral Subsite and Aneuploidy in OPMDs/OSCCs.

Castagnola P, Zoppoli G, Gandolfo S, Monticone M, Malacarne D, Cirmena G, Brown D, Aiello C, Maffei M, Marino R, Giaretti W, Pentenero M.

PLoS One. 2015 Nov 5;10(11):e0142294. doi: 10.1371/journal.pone.0142294. eCollection 2015.

19.

Genomic aberrations in young and elderly  breast cancer patients.

Azim HA Jr, Nguyen B, Brohée S, Zoppoli G, Sotiriou C.

BMC Med. 2015 Oct 15;13:266. doi: 10.1186/s12916-015-0504-3.

20.

Uncovering the genomic heterogeneity of multifocal breast cancer.

Desmedt C, Fumagalli D, Pietri E, Zoppoli G, Brown D, Nik-Zainal S, Gundem G, Rothé F, Majjaj S, Garuti A, Carminati E, Loi S, Van Brussel T, Boeckx B, Maetens M, Mudie L, Vincent D, Kheddoumi N, Serra L, Massa I, Ballestrero A, Amadori D, Salgado R, de Wind A, Lambrechts D, Piccart M, Larsimont D, Campbell PJ, Sotiriou C.

J Pathol. 2015 Aug;236(4):457-66. doi: 10.1002/path.4540. Epub 2015 May 7.

21.

Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies.

Tortolina L, Duffy DJ, Maffei M, Castagnino N, Carmody AM, Kolch W, Kholodenko BN, De Ambrosi C, Barla A, Biganzoli EM, Nencioni A, Patrone F, Ballestrero A, Zoppoli G, Verri A, Parodi S.

Oncotarget. 2015 Mar 10;6(7):5041-58.

22.

Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity.

Soncini D, Caffa I, Zoppoli G, Cea M, Cagnetta A, Passalacqua M, Mastracci L, Boero S, Montecucco F, Sociali G, Lasigliè D, Damonte P, Grozio A, Mannino E, Poggi A, D'Agostino VG, Monacelli F, Provenzani A, Odetti P, Ballestrero A, Bruzzone S, Nencioni A.

J Biol Chem. 2014 Dec 5;289(49):34189-204. doi: 10.1074/jbc.M114.594721. Epub 2014 Oct 20.

23.

Sequential dose-dense 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel in patients with early breast cancer with four or more positive lymph nodes.

Murialdo R, Gallo M, Boy D, Zoppoli G, Tixi L, Gonella R, Ballestrero A, Patrone F.

Tumori. 2014 Mar-Apr;100(2):128-35. doi: 10.1700/1491.16393.

PMID:
24852855
24.

Quantitative Real Time PCR assessment of hormonal receptors and HER2 status on fine-needle aspiration pre-operatory specimens from a prospectively accrued cohort of women with suspect breast malignant lesions.

Garuti A, Rocco I, Cirmena G, Chiaramondia M, Baccini P, Calabrese M, Palermo C, Friedman D, Zoppoli G, Ballestrero A.

Gynecol Oncol. 2014 Feb;132(2):389-96. doi: 10.1016/j.ygyno.2013.11.020. Epub 2013 Nov 21.

PMID:
24269902
25.

The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer.

Scabini S, Montecucco F, Nencioni A, Zoppoli G, Sartini M, Rimini E, Massobrio A, De Marini L, Poggi A, Boaretto R, Romairone E, Ballestrero A, Ferrando V.

World J Surg Oncol. 2013 Nov 18;11:292. doi: 10.1186/1477-7819-11-292.

26.

On biomarkers and pathways in rectal cancer: What's the target?

Zoppoli G, Ferrando V, Scabini S.

World J Gastrointest Surg. 2012 Dec 27;4(12):275-7. doi: 10.4240/wjgs.v4.i12.275.

27.

Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.

Dono M, Massucco C, Chiara S, Sonaglio C, Mora M, Truini A, Cerruti G, Zoppoli G, Ballestrero A, Truini M, Ferrarini M, Zupo S.

Mol Med. 2013 Feb 8;18:1519-26. doi: 10.2119/molmed.2012.00175.

28.

The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses.

Bauer I, Grozio A, Lasigliè D, Basile G, Sturla L, Magnone M, Sociali G, Soncini D, Caffa I, Poggi A, Zoppoli G, Cea M, Feldmann G, Mostoslavsky R, Ballestrero A, Patrone F, Bruzzone S, Nencioni A.

J Biol Chem. 2012 Nov 30;287(49):40924-37. doi: 10.1074/jbc.M112.405837. Epub 2012 Oct 18.

29.

Seasonal and pandemic (A/H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens.

Bedognetti D, Ansaldi F, Zanardi E, Durando P, Sertoli MR, Massucco C, Balleari E, Racchi O, Zoppoli G, Orsi A, Alicino C, Icardi G, Marincola FM, Zupo S, Ferrarini M, De Maria A.

Blood. 2012 Aug 30;120(9):1954-7. No abstract available.

30.

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.

Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, Doroshow JH, Pommier Y.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15030-5. doi: 10.1073/pnas.1205943109. Epub 2012 Aug 27.

31.

DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Solier S, Zhang YW, Ballestrero A, Pommier Y, Zoppoli G.

Curr Cancer Drug Targets. 2012 May;12(4):356-71. Review.

PMID:
22385513
32.

Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.

Ballestrero A, Garuti A, Cirmena G, Rocco I, Palermo C, Nencioni A, Scabini S, Zoppoli G, Parodi S, Patrone F.

Curr Cancer Drug Targets. 2012 May;12(4):316-28. Review.

PMID:
22385512
33.

Role of angiogenesis inhibitors in colorectal cancer: sensitive and insensitive tumors.

Bagnasco L, Piras D, Parodi S, Bauer I, Zoppoli G, Patrone F, Ballestrero A.

Curr Cancer Drug Targets. 2012 May;12(4):303-15. Review.

PMID:
22385510
34.

Identification of a predominant co-regulation among kinetochore genes, prospective regulatory elements, and association with genomic instability.

Reinhold WC, Erliandri I, Liu H, Zoppoli G, Pommier Y, Larionov V.

PLoS One. 2011;6(10):e25991. doi: 10.1371/journal.pone.0025991. Epub 2011 Oct 10.

35.

Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis.

Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, Engle AM, Thomas JM, Wang E, Marincola FM, Bedognetti D.

J Transl Med. 2011 Oct 12;9:174. doi: 10.1186/1479-5876-9-174.

36.

Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells.

Cea M, Soncini D, Fruscione F, Raffaghello L, Garuti A, Emionite L, Moran E, Magnone M, Zoppoli G, Reverberi D, Caffa I, Salis A, Cagnetta A, Bergamaschi M, Casciaro S, Pierri I, Damonte G, Ansaldi F, Gobbi M, Pistoia V, Ballestrero A, Patrone F, Bruzzone S, Nencioni A.

PLoS One. 2011;6(7):e22739. doi: 10.1371/journal.pone.0022739. Epub 2011 Jul 27.

37.

Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes.

Balleari E, Clavio M, Arboscello E, Bellodi A, Bruzzone A, Del Corso L, Lucchetti MV, Miglino M, Passalia C, Pierri I, Ponassi I, Oneto C, Racchi O, Scudeletti M, Vignolo L, Zoppoli G, Gobbi M, Ghio R.

Leuk Res. 2011 Nov;35(11):1472-6. doi: 10.1016/j.leukres.2011.05.025. Epub 2011 Jul 26.

PMID:
21794914
38.

CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.

Zoppoli G, Solier S, Reinhold WC, Liu H, Connelly JW Jr, Monks A, Shoemaker RH, Abaan OD, Davis SR, Meltzer PS, Doroshow JH, Pommier Y.

Oncogene. 2012 Jan 26;31(4):403-18. doi: 10.1038/onc.2011.283. Epub 2011 Jul 18. Erratum in: Oncogene. 2012 Jan 26;31(4):535-6.

PMID:
21765476
39.

Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC.

Zoppoli G, Douarre C, Dalla Rosa I, Liu H, Reinhold W, Pommier Y.

Nucleic Acids Res. 2011 Aug;39(15):6620-32. doi: 10.1093/nar/gkr208. Epub 2011 Apr 29.

40.

Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data.

Zoppoli G, Bianchi F, Bruzzone A, Calvia A, Oneto C, Passalia C, Balleari E, Bedognetti D, Ponomareva E, Nazzari E, Castelletti L, Castellan L, Minuto F, Ghio R, Ferone D.

Pituitary. 2012 Jun;15(2):209-14. doi: 10.1007/s11102-011-0311-6. Review.

PMID:
21503687
41.

Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S, Bruzzone A, Sertoli MR, Balleari E, Racchi O, Messina M, Caltabiano G, Icardi G, Durando P, Marincola FM, Boccardo F, Ferrarini M, Ansaldi F, De Maria A.

J Immunol. 2011 May 15;186(10):6044-55. doi: 10.4049/jimmunol.1004095. Epub 2011 Apr 15.

42.

Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.

Zoppoli G, Cea M, Soncini D, Fruscione F, Rudner J, Moran E, Caffa I, Bedognetti D, Motta G, Ghio R, Ferrando F, Ballestrero A, Parodi S, Belka C, Patrone F, Bruzzone S, Nencioni A.

Exp Hematol. 2010 Nov;38(11):979-88. doi: 10.1016/j.exphem.2010.07.013. Epub 2010 Aug 7.

PMID:
20696207
43.

Iodized oil pleural effusion in a patient previously treated with transarterial chemoembolization for hepatocellular carcinoma.

Negrini S, Zoppoli G, Andorno E, Picciotto A, Indiveri F.

Chest. 2010 Jul;138(1):193-5. doi: 10.1378/chest.09-2213.

PMID:
20605818
44.

Gynaecomastia: the anastrozole paradox.

Bedognetti D, Rubagotti A, Zoppoli G, Boccardo F.

J Pediatr Endocrinol Metab. 2010 Jan-Feb;23(1-2):205-6. No abstract available.

PMID:
20432826
45.

Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era.

Bedognetti D, Zoppoli G, Sertoli MR, Zanardi E, Blandini P, Uccellini L, Boccardo F, Andreoli GB, Ghio R, Racchi O, Ferrarini M, De Maria A.

Int J Hematol. 2010 Mar;91(2):342-4; author reply 345-6. doi: 10.1007/s12185-010-0522-z. Epub 2010 Feb 27. No abstract available.

PMID:
20191334
46.

Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.

Nencioni A, Cea M, Garuti A, Passalacqua M, Raffaghello L, Soncini D, Moran E, Zoppoli G, Pistoia V, Patrone F, Ballestrero A.

PLoS One. 2010 Feb 2;5(2):e9024. doi: 10.1371/journal.pone.0009024.

47.

Ras-induced resistance to lapatinib is overcome by MEK inhibition.

Zoppoli G, Moran E, Soncini D, Cea M, Garuti A, Rocco I, Cirmena G, Grillo V, Bagnasco L, Icardi G, Ansaldi F, Parodi S, Patrone F, Ballestrero A, Nencioni A.

Curr Cancer Drug Targets. 2010 Mar;10(2):168-75.

PMID:
20088787
48.

Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.

Bruzzone S, Fruscione F, Morando S, Ferrando T, Poggi A, Garuti A, D'Urso A, Selmo M, Benvenuto F, Cea M, Zoppoli G, Moran E, Soncini D, Ballestrero A, Sordat B, Patrone F, Mostoslavsky R, Uccelli A, Nencioni A.

PLoS One. 2009 Nov 19;4(11):e7897. doi: 10.1371/journal.pone.0007897.

49.

Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].

Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH 2nd, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH, Pommier Y.

J Pharmacol Exp Ther. 2009 Dec;331(3):816-26. doi: 10.1124/jpet.109.154997. Epub 2009 Sep 9.

50.

APO866 activity in hematologic malignancies: a preclinical in vitro study.

Cea M, Zoppoli G, Bruzzone S, Fruscione F, Moran E, Garuti A, Rocco I, Cirmena G, Casciaro S, Olcese F, Pierri I, Cagnetta A, Ferrando F, Ghio R, Gobbi M, Ballestrero A, Patrone F, Nencioni A.

Blood. 2009 Jun 4;113(23):6035-7; author reply 6037-8. doi: 10.1182/blood-2009-03-209213. No abstract available.

PMID:
19498032

Supplemental Content

Loading ...
Support Center